Slovak
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Odkaz sa uloží do schránky
PostavenieAktívny, bez náboru
Sponzori
University of Sao Paulo General Hospital

Kľúčové slová

Abstrakt

Hospitalization in pregnancy and childbirth greatly increases the thromboembolic risk of these patients. The application of a protocol for assessing the risk of VTE reduces mortality and morbidity of these phenomena.

Popis

Thromboembolic events are among the leading causes of maternal morbidity and mortality in pregnancy / postpartum period. They are the leading cause of maternal death in developed countries. Risk factors for venous thromboembolism (VTE) during pregnancy and postpartum as family history or personal history of VTE, thrombophilia, age over 35, obesity and high parity has been the most studied. One of the main risk factors is hospitalization, which increases up to 20 times the risk of VTE.

Objective: The objective of the study is to identify early risk factors for VTE in hospitalized pregnant women and institute appropriate prophylaxis to reduce the incidence and morbidity.

Methods: A prospective study that will evaluate all pregnant women admitted for clinical treatment and / or surgery in the Department of Obstetrics and Gynecology, Clinics Hospital, University of São Paulo through the application of a thromboprophylaxis protocol with risk assessment score. The patient in whom prophylaxis would be indicated are those with scores greater than or equal to 3. The drug to be used is enoxaparin and the dose to be used depends on the weight of the patient.

It will be further assessed: adverse effects of treatment with enoxaparin, protocol failure in the group treated and untreated (without anticoagulation) and bleeding incidence in the untreated group.

Risk score description: score 3 - previous thrombosis/thromboembolism, homozygous mutations, combined thrombophilia risk factors, antiphospholipid syndrome, cancer(stomach, pancreas, lung), inflammatory conditions, lupus, sickle cell disease, nephrotic syndrome, heart disease; Score 2 - Protein C deficiency, Protein S deficiency, heterozygous F5 Leiden, heterozygous F2 G20210A mutation, cancer(last 6 months), chemotherapy(last 6m), immobility, bed rest >4d prior to C-section, current serious infections, BMI≥40 kg/m2 , age≥40y, lung disease(cyanosis), postpartum hemorrhage >1L; Score 1 - age ≥ 35 and ≤39 y, parity ≥3, multiple pregnancy, hyperemesis, gross varicose veins, smoker ≥20, surgical procedure.

Termíny

Naposledy overené: 12/31/2019
Prvý príspevok: 10/29/2015
Odhadovaná registrácia bola odoslaná: 11/05/2015
Prvý príspevok: 11/08/2015
Posledná aktualizácia bola odoslaná: 01/20/2020
Posledná aktualizácia bola zverejnená: 01/22/2020
Aktuálny dátum začatia štúdie: 11/30/2014
Odhadovaný dátum dokončenia primárneho okruhu: 07/30/2019
Odhadovaný dátum dokončenia štúdie: 06/30/2020

Stav alebo choroba

Thrombophilia Associated With Pregnancy
Perioperative/Postoperative Complications
Venous Thrombosis
Pulmonary Embolism
Other Specified Risk Factors in Pregnancy
Deep Vein Thrombosis

Intervencia / liečba

Drug: enoxaparin

Other: no intervention

Fáza

-

Skupiny zbraní

ArmIntervencia / liečba
Other: enoxaparin
A prospective study that will evaluate all pregnant women admitted for clinical treatment and / or surgery through the application of a thromboprophylaxis protocol with risk assessment score.The patient in whom prophylaxis would be indicated are those with scores greater than or equal to 3. The drug to be used is enoxaparin and the dose to be used depends on the weight of the patient.It will be further assessed: adverse effects of treatment with enoxaparin, protocol failure in the group treated and untreated (without anticoagulation) and bleeding incidence in both groups.
Drug: enoxaparin
Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.
Other: no intervention
Pregnant women admitted in hospital for clinical treatment and/or delivery and that does not score for thromboprophylaxis.
Other: no intervention
Hospitalized patients that score less than three are not prescribed enoxaparin.

Kritériá oprávnenosti

Pohlavia vhodné na štúdiumFemale
Prijíma zdravých dobrovoľníkovÁno
Kritériá

Inclusion Criteria:

- All pregnant women hospitalized.

Exclusion Criteria:

- Previous use of anticoagulation

Výsledok

Primárne výstupné opatrenia

1. Number of hospitalized pregnant patients with venous thromboembolism (VTE), death and adverse events after applying an in hospital risk score for thrombosis at 12 weeks post discharge. [4 years]

Identify early risk factors for VTE in hospitalized pregnant women and prescribe appropriate prophylaxis to reduce the incidence, morbidity and mortality of VTE. The patients that score ≥ 3 will receive enoxaparin. This group will be analyzed for the incidence of adverse outcomes: VTE, bleeding, death until 3 months post hospitalization. This same analysis will be done in those patients who have not received heparin. The patients that could not receive heparin due to bleeding risk will be analyzed also. The analysis of the score will also describe if the higher the score, the higher the index of adverse events, mainly when it is not possible to prescribe the prophylaxis.

Pripojte sa k našej
facebookovej stránke

Najkompletnejšia databáza liečivých bylín podporovaná vedou

  • Pracuje v 55 jazykoch
  • Bylinné lieky podporené vedou
  • Rozpoznávanie bylín podľa obrázka
  • Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
  • Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
  • Vyhľadajte liečivé byliny podľa ich účinkov
  • Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi

Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume

Google Play badgeApp Store badge